Helping the Families of Treatment-Refusers

Alec Pollard, PhD

Founder and Director, Saint Louis Behavioral Medicine Institute Anxiety Disorders Center
Professor, Community and Family Medicine at Saint Louis University

Dr. Pollard gives advice to family members who live with someone who refuses treatment for OCD and anxiety disorders Dr. Pollard gives advice to family members who live with someone who refuses treatment for OCD and anxiety disorders and explains a strategy that teaches family members to shape treatment-seeking behavior in someone with an anxiety disorder.

Social Anxiety Disorder: Dosing Timing of D-cycloserine to Augment CBT

Eligibility Criteria
  • At least 18 years old
  • Have extreme fear and/or anxiety in social situations
  • Interested in receiving treatment for your social anxiety

This is a partial list of eligibility requirements. To inquire about your eligibility, please call 312-563-6687.

State
Illinois

We are seeking research volunteers at Rush University Medical Center who suffer from anxiety or fear in social situations.


The purpose of this study is to determine if a medication improves the effectiveness of cognitive-behavioral therapy (CBT) for the treatment of social anxiety disorder.

Spread the Word

Help us spread the word about the benefits of treatment for anxiety and mood disorders, OCD, and PTSD — for children and teens, women, men, and all those suffering from related illnesses.

Please tweet, post on Facebook, or add the links to your own website — whatever works to get the word out that you are not alone and help is here!

Identification of Neural Predictors of Response to Cognitive Behavioral Therapy in Depression and Anxiety

Eligibility Criteria

18 to 25 years old
Suffering from depression
OR
18 to 55 years old
Suffering from an anxiety disorder

 

Exclusion Criteria

Volunteers may not have metal in their body.

State
Illinois

This study is testing to see what behavior and brain function can tell us about treatment success in depression using cognitive-behavioral therapy, a standard psychotherapy treatment for depressive disorders.
AND
The study purpose is to evaluate what brain function can tell us about treatment success in anxiety disorders.

Time commitment is about 33 hours over 22 visits.

Volunteers will participate in the following:

Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder

Eligibility Criteria
  • Male or female outpatients 18 or older with a primary psychiatric diagnosis (designated by the patient as the most important source of current distress) of social anxiety disorder as defined by DSM-5 criteria 
  • A total score ? 60 on the LSAS 
  • Physical examination and laboratory findings without clinically significant abnormalities 
  • Willingness and ability to participate in the informed consent process and comply with the requirements of the study protocol
Exclusion Criteria
  • A lifetime history of bipolar disorder, schizophrenia, psychosis, delusional disorders, or obsessive-compulsive disorder; an eating disorder in the past 6 months; organic brain syndrome, mental retardation or other cognitive dysfunction that could interfere with capacity to engage in therapy; a history of substance or alcohol abuse or dependence (other than nicotine) in the last 6 months or otherwise unable to commit to refraining from alcohol use during the acute period of study participation
  • PTSD within the past 6 months. Entry of patients with other mood or anxiety disorders will be permitted if the social anxiety disorder is judged to be the predominant disorder, in order to increase accrual of a clinically relevant sample. Patients with significant suicidal ideation (MADRS item 10 score > 3) or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention.
  • Patients must be off concurrent psychotropic medication (e.g., antidepressants, anxiolytics, beta blockers) for at least 2 weeks prior to initiation of randomized treatment.
  • Significant personality dysfunction likely to interfere with study participation
  • Serious medical illness or instability for which hospitalization may be likely within the next year
  • Patients with a current or past history of seizures
  • Pregnant and lactating women, and women of childbearing potential who are not using medically accepted forms of contraception (e.g., IUD, oral contraceptives, barrier devices, condoms and foam, or implanted progesterone rods stabilized for at least 3 months)
  • Any concurrent psychotherapy initiated within 3 months of baseline, or ongoing psychotherapy of any duration directed specifically toward treatment of the SAD is excluded. Prohibited psychotherapy includes CBT or psychodynamic therapy focusing on exploring specific, dynamic causes of the phobic symptomatology and providing management skills. General supportive therapy initiated more than 3 months prior is acceptable.
  • Prior non-response to adequately-delivered exposure (as defined by the patient?s report of receiving specific and regular exposure assignments as part of a previous treatment).
  • Patients with a history of head trauma causing loss of consciousness, seizure or ongoing cognitive impairment. Current use of isoniazid or ethionamide compounds
  • Insufficient command of the English language

 

State
Texas

The first purpose is to evaluate the efficacy of d-cycloserine (DCS) in augmenting treatment for social anxiety disorder. Individuals will receive 5 weeks of cognitive-behavioral therapy (CBT), randomized into one of four treatment groups. Participants will receive either one pill of DSC or one placebo pill, both one hour prior to sessions 2, 3, 4, and 5 and immediately afterward. The investigators hypothesize that individuals receiving post-session DCS will show a greater decrease in social anxiety symptoms after receiving CBT.

PODCASTS

VIDEOS